PTC Therapeutics, Inc. Reports Third Quarter Financial Results And Provides Corporate Update

For the first time in the company's history, we recognized revenue from the sale of Translarna for the treatment of Duchenne muscular dystrophy through our European reimbursed early access programs. Furthermore, before the end of the year, we plan to begin submitting a New Drug Application with the FDA on a rolling basis for Translarna as a treatment for nonsense mutation Duchenne muscular dystrophy .

http://ift.tt/1y9N8GB